Wall Street analysts expect that Hill-Rom Holdings, Inc. (NYSE:HRC) will post $750.60 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Hill-Rom’s earnings. The highest sales estimate is $753.80 million and the lowest is $745.80 million. Hill-Rom posted sales of $738.30 million during the same quarter last year, which indicates a positive year over year growth rate of 1.7%. The business is expected to report its next quarterly earnings results on Friday, November 2nd.
On average, analysts expect that Hill-Rom will report full year sales of $2.84 billion for the current year, with estimates ranging from $2.83 billion to $2.84 billion. For the next financial year, analysts anticipate that the firm will post sales of $2.92 billion per share, with estimates ranging from $2.89 billion to $2.95 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Hill-Rom.
Hill-Rom (NYSE:HRC) last released its earnings results on Friday, July 27th. The medical technology company reported $1.15 EPS for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.02. The business had revenue of $708.60 million for the quarter, compared to analysts’ expectations of $707.50 million. Hill-Rom had a return on equity of 20.54% and a net margin of 8.19%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.91 earnings per share.
Several analysts have issued reports on HRC shares. ValuEngine upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating in a research report on Tuesday, July 31st. Northcoast Research restated a “buy” rating and set a $104.00 price target on shares of Hill-Rom in a research report on Tuesday, July 31st. Zacks Investment Research upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $98.00 price target for the company in a research report on Monday, July 2nd. Raymond James upped their price target on shares of Hill-Rom from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, July 30th. Finally, KeyCorp upped their price target on shares of Hill-Rom from $97.00 to $115.00 and gave the company an “overweight” rating in a research report on Tuesday, July 17th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $100.00.
NYSE HRC opened at $97.06 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 1.24. Hill-Rom has a 12-month low of $71.91 and a 12-month high of $98.96. The stock has a market cap of $6.36 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 1.49 and a beta of 0.89.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 21st will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, September 20th. This represents a $0.80 annualized dividend and a yield of 0.82%. Hill-Rom’s payout ratio is 20.73%.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its holdings in shares of Hill-Rom by 0.3% during the first quarter. Wells Fargo & Company MN now owns 1,087,958 shares of the medical technology company’s stock worth $94,653,000 after purchasing an additional 3,671 shares during the period. Swiss National Bank boosted its holdings in shares of Hill-Rom by 2.2% during the first quarter. Swiss National Bank now owns 114,700 shares of the medical technology company’s stock worth $9,979,000 after purchasing an additional 2,500 shares during the period. Chicago Equity Partners LLC purchased a new stake in shares of Hill-Rom during the first quarter worth about $472,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of Hill-Rom by 3.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 738,453 shares of the medical technology company’s stock worth $64,246,000 after purchasing an additional 25,381 shares during the period. Finally, ETRADE Capital Management LLC boosted its holdings in shares of Hill-Rom by 11.6% during the first quarter. ETRADE Capital Management LLC now owns 8,386 shares of the medical technology company’s stock worth $730,000 after purchasing an additional 869 shares during the period. Institutional investors and hedge funds own 84.84% of the company’s stock.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Story: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.